Expertise in
6
conditions

Dr. Steven Kempers

Dermatology
Office
7205 University Ave NE, 
Minneapolis, MN 
Referral may be required
Before you request
Expertise in
6
conditions
Office
7205 University Ave NE, 
Minneapolis, MN 

Overview

Steven Kempers is a Dermatologist practicing medicine in Minneapolis, Minnesota.

Dr. Kempers is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Fetal Retinoid Syndrome, and Actinic Keratosis.

He is actively involved in clinical research, co-authoring 30 peer reviewed articles and participating in 13 clinical trials.

Specialties

Dermatology

Licenses

Specialist in MN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Metropolitan Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
7205 University Ave NE, Minneapolis, MN 55432
Other Locations
Office
119 14th St NW, New Brighton, MN 55112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
Enrollment Status: Completed
Publish Date: September 07, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

30 Total Publications

Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure.
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure.
Journal: British journal of clinical pharmacology
Published: August 05, 2025
Similar Doctors
Expertise in
53
conditions
Dr. Sara A. Hylwa
Dermatology
Expertise in
53
conditions
Dr. Sara A. Hylwa
Dermatology
Referral may be required

Park Nicollet Contact Dermatitis Clinic

7550 34th Ave S, 
Minneapolis, MN 
 (18.5 miles away)
952-993-3260
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

As a dermatologist specializing in contact dermatitis, I enjoy seeing patients of all backgrounds and ages to try to help them learn more about their rashes through patch testing. My goal is to make each patient’s patch test experience a positive one and to help them make any necessary lifestyle changes based on the results of the testing. In my free time, I enjoy spending time with my husband and friends, running (including the completion of marathons), yoga, cooking and baking. Dr. Hylwa is highly rated in 53 conditions, according to our data. Her clinical expertise encompasses Contact Dermatitis, Erythema Multiforme, Stevens-Johnson Syndrome, and Comedones. Dr. Hylwa is currently accepting new patients.

Expertise in
5
conditions
Dr. Noah Goldfarb
Dermatology
Expertise in
5
conditions
Dr. Noah Goldfarb
Dermatology
Referral may be required

M Health Fairview Dermatology Clinic Minneapolis

909 Fulton Street Southeast, Floor 3, 
Minneapolis, MN 
 (13.3 miles away)
612-625-5656
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Goldfarb is a Dermatologist practicing medicine in Minneapolis, Minnesota. He has been practicing medicine for over 17 years. Dr. Goldfarb is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hidradenitis Suppurativa, Basal Cell Skin Cancer, Dissecting Cellulitis of the Scalp, and Hypocomplementemic Urticarial Vasculitis. Dr. Goldfarb is board certified in Dermatology: American Board Of Dermatology, 2014 and Internal Medicine: American Board Of Internal Medicine, 2014. Dr. Goldfarb is currently accepting new patients.

Expertise in
12
conditions
Dr. Maria Hordinsky
Pediatrics | Dermatology
Expertise in
12
conditions
Dr. Maria Hordinsky
Pediatrics | Dermatology
Referral may be required

M Health Fairview Discovery Pediatric Specialty Clinic

2512 South 7th Street, Floor 3, 
Minneapolis, MN 
 (13.6 miles away)
612-365-6777
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maria Hordinsky is a Pediatrics specialist and a Dermatologist practicing medicine in Minneapolis, Minnesota. Dr. Hordinsky is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Alopecia Areata, Graham-Little-Piccardi-Lassueur Syndrome, and Alopecia Universalis. Dr. Hordinsky is board certified in Dermatology: American Board Of Dermatology, 1980.

Frequently Asked Questions about Dr. Steven Kempers

How do I make an appointment with Dr. Steven Kempers?

You can book an appointment with Dr. Steven Kempers by calling their office at 763-571-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Steven Kempers a top-rated expert for Lamellar Ichthyosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Steven Kempers is classified as an Elite expert for Lamellar Ichthyosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Steven Kempers specialize in?

While Dr. Steven Kempers is a Dermatology, they have specific expertise in Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, and Fetal Retinoid Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Steven Kempers participate in research or clinical trials?

Yes. Dr. Steven Kempers has published 30 articles and abstracts on conditions like Lamellar Ichthyosis. You can view a list of Dr. Steven Kempers's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Steven Kempers accept my insurance?

Dr. Steven Kempers accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 763-571-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kempers's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile